Abstract
SCH 39304 was compared with fluconazole and ketoconazole in a systemic Candida albicans infection in mice (10(6) CFU per mouse). Results were based on survival rates and CFU in kidneys following once-daily oral treatment of 2, 5, or 10 days duration. In normal mice, SCH 39304 (dose to reduce kidney counts by 4 log units, 0.5 mg/kg of body weight) was 3 and 200 times more active than fluconazole and ketoconazole, respectively. In immunocompromised mice (gamma irradiation, 600 rads), SCH 39304 (dose to reduce kidney counts by 4 log units, 1.3 mg/kg) was 35 and greater than 100 times more active than fluconazole and ketoconazole, respectively. In normal mice, when the infecting inoculum varied from 10(5) to 10(7) CFU, only a fivefold increase in the dose to reduce kidney counts by 4 log units was observed with SCH 39304. Excellent protection was also seen when mice were treated with a single oral dose of SCH 39304 up to 24 h prior to infection with C. albicans. Studies in a systemic C. albicans infection model indicated that SCH 39304 is equally efficacious following either oral or intravenous administration. In a systemic Aspergillus flavus infection, mice treated with SCH 39304 (5 mg/kg) survived twice as long (16 days) as those treated with fluconazole (50 mg/kg) or controls did.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Clemons K. V., Hanson L. H., Perlman A. M., Stevens D. A. Efficacy of SCH39304 and fluconazole in a murine model of disseminated coccidioidomycosis. Antimicrob Agents Chemother. 1990 May;34(5):928–930. doi: 10.1128/aac.34.5.928. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cook R. A., McIntyre K. A., Galgiani J. N. Effects of incubation temperature, inoculum size, and medium on agreement of macro- and microdilution broth susceptibility test results for yeasts. Antimicrob Agents Chemother. 1990 Aug;34(8):1542–1545. doi: 10.1128/aac.34.8.1542. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Defaveri J., Sun S. H., Graybill J. R. Treatment of murine coccidioidal meningitis with SCH39304. Antimicrob Agents Chemother. 1990 Apr;34(4):663–664. doi: 10.1128/aac.34.4.663. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fainstein V., Bodey G. P., Elting L., Maksymiuk A., Keating M., McCredie K. B. Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients. Antimicrob Agents Chemother. 1987 Jan;31(1):11–15. doi: 10.1128/aac.31.1.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kobayashi G. S., Travis S. J., Rinaldi M. G., Medoff G. In vitro and in vivo activities of Sch 39304, fluconazole, and amphotericin B against Histoplasma capsulatum. Antimicrob Agents Chemother. 1990 Apr;34(4):524–528. doi: 10.1128/aac.34.4.524. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McIntyre K. A., Galgiani J. N. In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy. Antimicrob Agents Chemother. 1989 Jul;33(7):1095–1100. doi: 10.1128/aac.33.7.1095. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Meunier F., Lambert C., Van der Auwera P. In-vitro activity of SCH39304 in comparison with amphotericin B and fluconazole. J Antimicrob Chemother. 1990 Feb;25(2):227–236. doi: 10.1093/jac/25.2.227. [DOI] [PubMed] [Google Scholar]
- Perfect J. R., Wright K. A., Hobbs M. M., Durack D. T. Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304. Antimicrob Agents Chemother. 1989 Oct;33(10):1735–1740. doi: 10.1128/aac.33.10.1735. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Restrepo B. I., Ahrens J., Graybill J. R. Efficacy of SCH39304 in murine cryptococcosis. Antimicrob Agents Chemother. 1989 Aug;33(8):1242–1246. doi: 10.1128/aac.33.8.1242. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Richardson K., Brammer K. W., Marriott M. S., Troke P. F. Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes. Antimicrob Agents Chemother. 1985 May;27(5):832–835. doi: 10.1128/aac.27.5.832. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sugar A. M., Picard M., Noble L. Treatment of murine pulmonary blastomycosis with SCH 39304, a new triazole antifungal agent. Antimicrob Agents Chemother. 1990 May;34(5):896–898. doi: 10.1128/aac.34.5.896. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tanio T., Ichise K., Nakajima T., Okuda T. In vivo efficacy of SM-8668 (Sch 39304), a new oral triazole antifungal agent. Antimicrob Agents Chemother. 1990 Jun;34(6):980–984. doi: 10.1128/aac.34.6.980. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Troke P. F., Andrews R. J., Brammer K. W., Marriott M. S., Richardson K. Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice. Antimicrob Agents Chemother. 1985 Dec;28(6):815–818. doi: 10.1128/aac.28.6.815. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Walsh T. J., Lee J. W., Lecciones J., Kelly P., Peter J., Thomas V., Bacher J., Pizzo P. A. SCH-39304 in prevention and treatment of disseminated candidiasis in persistently granulocytopenic rabbits. Antimicrob Agents Chemother. 1990 Aug;34(8):1560–1564. doi: 10.1128/aac.34.8.1560. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Yoshida Y., Aoyama Y. Interaction of azole antifungal agents with cytochrome P-45014DM purified from Saccharomyces cerevisiae microsomes. Biochem Pharmacol. 1987 Jan 15;36(2):229–235. doi: 10.1016/0006-2952(87)90694-0. [DOI] [PubMed] [Google Scholar]